| 1 |
34530900 | Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma. | 2021 Sep 16 |
1 |
| 2 |
34832966 | In Vitro Assessment of the Role of p53 on Chemotherapy Treatments in Neuroblastoma Cell Lines. | 2021 Nov 19 |
1 |
| 3 |
33153480 | Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells. | 2020 Nov 5 |
1 |
| 4 |
29295500 | Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells. | 2017 Dec 23 |
1 |
| 5 |
26414189 | Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support. | 2016 |
1 |
| 6 |
27693638 | DNA-PKcs, a novel functional target of acriflavine, mediates acriflavine's p53-dependent synergistic anti-tumor efficiency with melphalan. | 2016 Dec 1 |
1 |
| 7 |
24089038 | Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis. | 2014 May |
1 |
| 8 |
24308434 | Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. | 2014 Sep |
2 |
| 9 |
24913980 | Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1. | 2014 Jul 15 |
1 |
| 10 |
25051404 | Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma. | 2014 Sep 23 |
1 |
| 11 |
22653969 | The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. | 2012 Aug |
1 |
| 12 |
19417135 | Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts. | 2009 May 15 |
1 |
| 13 |
18095870 | Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells. | 2008 Jan |
1 |
| 14 |
18024399 | Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. | 2007 Nov |
2 |
| 15 |
15883412 | Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome. | 2005 Jul 1 |
2 |
| 16 |
15308759 | p53 elevation in relation to levels and cytotoxicity of mono- and bifunctional melphalan-DNA adducts. | 2004 Nov |
2 |
| 17 |
14555520 | Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. | 2003 Oct 1 |
3 |
| 18 |
11507071 | Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. | 2001 Aug 15 |
5 |
| 19 |
11050000 | Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. | 2000 Nov 1 |
2 |
| 20 |
11096420 | Abrogation of G(2)/M-phase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin in TP53 mutant human tumor cells. | 2000 Dec |
2 |
| 21 |
11107118 | p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. | 2000 Dec |
2 |
| 22 |
8706243 | Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein. | 1996 Jul |
1 |